U.K. RECOVERY trial’s expansion to Asia, Africa sites offers access to broader scope of patients, ‘safety net’

By expanding into sites outside the U.K., the RECOVERY master protocol trial will be able to evaluate the efficacy of repurposed and investigational COVID-19 therapies in populations with less background healthcare treatment and different co-morbidities. 

Peter Horby, RECOVERY’s joint chief investigator, told BioCentury that having international sites also serves as a “safety net” so the trial can continue even if the U.K. sees a dramatic decline in COVID-19 cases over the next several months. ...